The study tracked patients for more than five years (median 60.7 months), with protection against disease returning emerging in under four months and continuing long term
The approved product is the generic equivalent of Sutab® Tablets developed by Azurity Pharmaceuticals
BPDCN typically presents with skin lesions before rapidly spreading to the bone marrow, lymph nodes
Hikal’s Q4 profit remained sharply lower year-on-year, falling 71% from Rs. 50.2 crore in Q4 FY25 as the company absorbed regulatory pressures and strategic accounting adjustments
The Establishment Inspection Report came following closure of a product- specific pre-approval inspection from March 2 to March 7, 2026
For the full year, standalone gross revenue crossed Rs. 1,700 crore
Clearance marks major shift beyond chemotherapy
Biologics manufacturing veteran brings over two decades of expertise in biosimilars, GMP operations, and large-scale biopharmaceutical manufacturing
Net profit stood at Rs. 921 crore for the quarter, while Europe revenues surged 30.2% YoY to Rs. 2,795 crore
The product has received tentative USFDA approval, Health Canada notice of compliance, and Indian regulatory approval
Subscribe To Our Newsletter & Stay Updated
